<DOC>
	<DOC>NCT00405054</DOC>
	<brief_summary>This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.</brief_summary>
	<brief_title>A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia) and Ph+ALL (Philadelphia chromosomepositive acute lymphoblastic leukemia) Patients must have adequate organ function Patients must have documented T315I mutation Patients within 3 months of allogeneic bone marrow transplant or not fully recovered from previous antileukemia therapy Patients with uncontrolled congestive heart failure Patients with active or uncontrolled infection or active Hepatitis B or C Patients with known HIV positivity or AIDS related illness Patients with currently active second malignancy, other than nonmelanoma skin cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>